- Home
- COSM vs KZIA Comparison
COSM vs KZIA Comparison
Compare COSM & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COSM
- KZIA
- Stock Information
- Founded
- COSM 2009
- KZIA 1994
- Country
- COSM United States
- KZIA Australia
- Employees
- COSM N/A
- KZIA N/A
- Industry
- COSM Other Pharmaceuticals
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- COSM Health Care
- KZIA Health Care
- Exchange
- COSM Nasdaq
- KZIA Nasdaq
- Market Cap
- COSM 12.3M
- KZIA 11.7M
- IPO Year
- COSM 2013
- KZIA 1999
- Fundamental
- Price
- COSM $0.80
- KZIA $8.33
- Analyst Decision
- COSM
- KZIA Strong Buy
- Analyst Count
- COSM 0
- KZIA 2
- Target Price
- COSM N/A
- KZIA $14.00
- AVG Volume (30 Days)
- COSM 1.5M
- KZIA 73.2K
- Earning Date
- COSM 08-18-2025
- KZIA 08-19-2025
- Dividend Yield
- COSM N/A
- KZIA N/A
- EPS Growth
- COSM N/A
- KZIA N/A
- EPS
- COSM N/A
- KZIA N/A
- Revenue
- COSM $53,554,457.00
- KZIA $1,549,158.00
- Revenue This Year
- COSM $28.14
- KZIA N/A
- Revenue Next Year
- COSM N/A
- KZIA $49.25
- P/E Ratio
- COSM N/A
- KZIA N/A
- Revenue Growth
- COSM N/A
- KZIA 248983.08
- 52 Week Low
- COSM $0.28
- KZIA $2.86
- 52 Week High
- COSM $1.58
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- COSM 56.06
- KZIA 47.95
- Support Level
- COSM $0.74
- KZIA $7.58
- Resistance Level
- COSM $1.28
- KZIA $8.99
- Average True Range (ATR)
- COSM 0.18
- KZIA 0.67
- MACD
- COSM -0.01
- KZIA -0.16
- Stochastic Oscillator
- COSM 36.02
- KZIA 34.61
About COSM Cosmos Health Inc.
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.